NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline

Reuters

16 Jun

NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline

ZURICH, June 16, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company, has announced an anticipated merger with Kadimastem. This strategic move is expected to unite NLS Pharmaceutics' proprietary DOXA platform with Kadimastem's cell-therapy assets, marking a transformational pivot for the company. The combined entity will be named NewcelX and aims to be a Nasdaq-listed clinical-stage biotech, featuring a robust pipeline that includes treatments for neurodegenerative diseases, diabetes, and central nervous system disorders. The merger is expected to close in the near future, setting the stage for an energized integration phase and accelerated clinical momentum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-054486), on June 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2543671027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543671027\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543671027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543671027","market":"fut","top_or_hot":-1,"title":"NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZURICH, June 16, 2025 - <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company, has announced an anticipated merger with Kadimastem. This strategic move is expected to unite NLS Pharmaceutics' proprietary DOXA platform with Kadimastem's cell-therapy assets, marking a transformational pivot for the company. The combined entity will be named NewcelX and aims to be a Nasdaq-listed clinical-stage biotech, featuring a robust pipeline that includes treatments for neurodegenerative diseases, diabetes, and central nervous system disorders. The merger is expected to close in the near future, setting the stage for an energized integration phase and accelerated clinical momentum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-054486), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZURICH, June 16, 2025 - <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company, has announced an anticipated merger with Kadimastem. This strategic move is expected to unite NLS Pharmaceutics' proprietary DOXA platform with Kadimastem's cell-therapy assets, marking a transformational pivot for the company. The combined entity will be named NewcelX and aims to be a Nasdaq-listed clinical-stage biotech, featuring a robust pipeline that includes treatments for neurodegenerative diseases, diabetes, and central nervous system disorders. The merger is expected to close in the near future, setting the stage for an energized integration phase and accelerated clinical momentum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-054486), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDLXcCb3:1","article_id":"2543671027","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543671027","pubTimestamp":1750073456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ZURICH, June 16, 2025 - NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company, has announced an anticipated merger with Kadimastem. This strategic move is expected to unite NLS Pharmaceutics' proprietary DOXA platform with Kadimastem's cell-therapy assets, marking a transformational pivot for the company. The combined entity will be named NewcelX and aims to be a Nasdaq-listed clinical-stage biotech, featuring a robust pipeline that includes treatments for neurodegenerative diseases, diabetes, and central nervous system disorders. The merger is expected to close in the near future, setting the stage for an energized integration phase and accelerated clinical momentum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NLSP":"NLS Pharmaceutics Ltd."},"translate_title":"NLS Pharmaceutics AG宣布即将与Kadimastem合并，计划组建NewcelX并扩大临床管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NLSP":0.9},"content_text":"NLS Pharmaceutics AG Announces Imminent Merger with Kadimastem, Plans to Form NewcelX with Expanded Clinical Pipeline\n    \n\n        ZURICH, June 16, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company, has announced an anticipated merger with Kadimastem. This strategic move is expected to unite NLS Pharmaceutics' proprietary DOXA platform with Kadimastem's cell-therapy assets, marking a transformational pivot for the company. The combined entity will be named NewcelX and aims to be a Nasdaq-listed clinical-stage biotech, featuring a robust pipeline that includes treatments for neurodegenerative diseases, diabetes, and central nervous system disorders. The merger is expected to close in the near future, setting the stage for an energized integration phase and accelerated clinical momentum.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-054486), on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}